Key Takeaways:
Glasgow-based EnteroBiotix has secured £19 million ($25 million) in new financing to take its lead microbiome therapy into a large-scale Phase 2b clinical trial for Irritable Bowel Syndrome with Constipation (IBS-C), a condition affecting over 10 million people in the US and Europe.
"Following the positive outcome of our Phase 2a TrIuMPH trial... we are now commencing the largest ever full-spectrum microbiome therapeutic trial in IBS," Dr. James McIlroy, CEO of EnteroBiotix, said. The trial is designed to "position EBX-102-02 as a potential first disease-modifying therapy for IBS-C, a highly debilitating condition... where unmet need has persisted for decades.”
The financing, led by Thairm Bio and the Scottish National Investment Bank, will fund the ‘Restoring Intestinal Symbiosis for Efficacy in IBS’ (RISE) trial. The study will enroll approximately 300 patients with moderate-to-severe IBS-C across the UK, with the first patient expected to be dosed in the second quarter of 2026 and topline data anticipated in the second half of 2027.
This late-stage trial builds on positive results from the company's 122-patient Phase 2a study, which showed clear efficacy signals for the therapeutic over placebo. For investors, the trial's success could validate the company's full-spectrum microbiome approach and unlock a significant market, potentially making it a first-in-class, disease-modifying option rather than a purely symptomatic treatment.
EnteroBiotix’s lead candidate, EBX-102-02, is an orally delivered, full-spectrum microbiome therapeutic. Unlike targeted probiotic or single-strain therapies, this approach aims to deliver a diverse and complete microbial ecosystem to restore gut symbiosis. The company's proprietary manufacturing process is designed to ensure the stability and viability of this complex community of microbes, which is considered a key challenge in the field.
The market for IBS treatments is crowded with therapies that primarily manage symptoms. A therapy that could be "disease-modifying," as EnteroBiotix suggests, would represent a significant shift. The RISE trial is one of the largest ever for a full-spectrum microbiome product, signaling growing confidence from investors in the gut microbiome as a viable therapeutic target for complex conditions like IBS.
This article is for informational purposes only and does not constitute investment advice.
